Amplifica to Present Positive Clinical Outcomes for AMP-303 at the Society for Investigative Dermatology Annual Meeting
Poster Highlights First-in-Human Results for the Treatment of Androgenetic AlopeciaSan
Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
First-in-Human Trial Demonstrates Promising Results for the Treatment of
Amplifica Announces First-in-Human Study Initiated
Amplifica’s AMP-303 safety and tolerability study targeting hair loss
Amplifica Expands Pipeline for Hair Loss
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage ProteinSAN
Amplifica Completes $11.8 Million Series A Financing to Enable Clinical Development of Lead Products to Treat Androgenic Alopecia
SAN DIEGO, CA - Amplifica Holdings Group, Inc. (“Amplifica”),